

PATENT COOPERATION TREATY

PCT

10/534253

10 JAN 2005

WIPO

PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or agent's file reference PCA31168/HMY	FOR FURTHER ACTION See Notification of Transmittal of International Preliminary Examination Report (Form PCT/IPEA/416)	
International application No. PCT/KR2003/002441	International filing date (day/month/year) 13 NOVEMBER 2003 (13.11.2003)	Priority date (day/month/year) 13 NOVEMBER 2002 (13.11.2002)
International Patent Classification (IPC) or national classification and IPC IPC7 A61K 9/14		
Applicant HANMI PHARM. CO., LTD. et al		

1. This international preliminary examination report has been prepared by this International Preliminary Examining Authority and is transmitted to the applicant according to Article 36.



2. This REPORT consists of a total of 3 sheets, including this cover sheet.

☐ This report is also accompanied by ANNEXES, i.e., sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT).

These annexes consist of a total of _____ sheets.

3. This report contains indications relating to the following items:

- I ☒ Basis of the report
- II ☐ Priority
- III ☐ Non-establishment of opinion with regard to novelty, inventive step and industrial applicability
- IV ☐ Lack of unity of invention
- V ☒ Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement
- VI ☐ Certain documents cited
- VII ☐ Certain defects in the international application
- VIII ☐ Certain observations on the international application

Date of submission of the demand 03 JUNE 2004 (03.06.2004)	Date of completion of this report 27 DECEMBER 2004 (27.12.2004)
Name and mailing address of the IPEA/KR  Korean Intellectual Property Office 920 Dunsan-dong, Seo-gu, Daejeon 302-701, Republic of Korea Facsimile No. 82-42-472-7140	Authorized officer Yoon, Kyung Ae Telephone No. 82-42-481-5605 

I. Basis of the report

1. With regard to the elements of the international application:*

- ☒ the international application as originally filed
- ☐ the description:
pages _____, as originally filed
pages _____, filed with the demand
pages _____, filed with the letter of _____
- ☐ the claims:
pages _____, as originally filed
pages _____, as amended (together with any statement) under Article 19
pages _____, filed with the demand
pages _____, filed with the letter of _____
- ☐ the drawings:
pages _____, as originally filed
pages _____, filed with the demand
pages _____, filed with the letter of _____
- ☐ the sequence listing part of the description:
pages _____, as originally filed
pages _____, filed with the demand
pages _____, filed with the letter of _____

2. With regard to the language, all the elements marked above were available or furnished to this Authority in the language in which the international application was filed, unless otherwise indicated under this item.

These elements were available or furnished to this Authority in the following language English which is

- ☐ the language of a translation furnished for the purposes of international search (under Rule 23.1(b)).
- ☒ the language of publication of the international application (under Rule 48.3(b)).
- ☐ the language of the translation furnished for the purposes of international preliminary examination (under Rules 55.2 and/or 55.3).

3. With regard to any nucleotide and/or amino acid sequence disclosed in the international application, the international preliminary examination was carried out on the basis of the sequence listing:

- ☐ contained in the international application in written form.
- ☐ filed together with the international application in computer readable form.
- ☐ furnished subsequently to this Authority in written form.
- ☐ furnished subsequently to this Authority in computer readable form.
- ☐ The statement that the subsequently furnished written sequence listing does not go beyond the disclosure in the international application as filed has been furnished.
- ☐ The statement that the information recorded in computer readable form is identical to the written sequence listing has been furnished.

4. ☐ The amendments have resulted in the cancellation of:

- ☐ the description, pages _____
- ☐ the claims, Nos. _____
- ☐ the drawings, sheets _____

5. ☐ This report has been established as if (some of) the amendments had not been made, since they have been considered to go beyond the disclosure as filed, as indicated in the Supplemental Box (Rule 70.2(c)).**

* Replacement sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this opinion as "originally filed." and are not annexed to this report since they do not contain amendments (Rules 70.16 and 70.17).

** Any replacement sheet containing such amendments must be referred to under item I and annexed to this report.

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement**1. Statement**

Novelty (N)	Claims	1-13	YES
	Claims	none	NO
Inventive step (IS)	Claims	1-13	YES
	Claims	none	NO
Industrial applicability (IA)	Claims	1-13	YES
	Claims	none	NO

2. Citations and explanations (Rule 70.7)

The present invention relates to a method for the preparation of paclitaxel solid dispersion by using the supercritical fluid process and paclitaxel solid dispersion prepared thereby.

The following documents have been considered for the purpose of this report:

D1 = WO 01-62753 A1 (30. 08. 2001)

D2 = WO 02-30466 A2 (18. 04. 2002)

D3 = WO 00-50007 A1 (31. 08. 2000)

D4 = US 6338859 B1 (15. 01. 2002)

1. Novelty and Inventive Step

D1 discloses methods for isolating taxol using supercritical fluid and a cosolvent extraction step from source materials.

D2 discloses a pharmaceutical composition comprising paclitaxel and a solubilizing compound selected from the group consisting of hydrotropic agent monomers, hydrotropic polymers, and hydrotropic hydrogels.

D3 discloses a triglyceride-free pharmaceutical composition comprising a hydrophobic therapeutic agent a carrier (a mixture of a hydrophilic surfactant and a hydrophobic surfactant)

D4 discloses a micelle-foaming composition comprising a therapeutic agent and a hydrophobic core surrounded by a hydrophilic shell (PVP).

However, none of the documents D1-D4 disclose a highly uniform nano-scale paclitaxel solid dispersion prepared by using the supercritical fluid process. Accordingly, the present invention is not considered to be easily invented from the invention disclosed in D1-D4 by a person skilled in the art. Therefore, the novelty and inventive step of the present invention can be acknowledged, and claims 1 to 13 meet the requirements of PCT Article 33(2) and 33(3).

2. Industrial Applicability

Claims 1 to 13 appear to meet the requirement of PCT Article 33(4).